Esophageal Squamous Cell Carcinoma
Conditions
Interventions
case series:neoadjuvant combined immunotherapy and chemotherapy
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
46 Years to 83 Years
Inclusion criteria
Inclusion criteria: All patients with esophageal squamous cell carcinoma who received neoadjuvant immunotherapy combined with chemotherapy in the Thoracic Surgery Department of the First Affiliated Hospital of Zhejiang University School of Medicine from May 2019 to May 2021.
Exclusion criteria
Exclusion criteria: 1. Lack of pre-treatment imaging assessment; 2. Image evaluation less than 2 times; 3. Previously received surgery or endoscopic interventional therapy for ESCC; 4. Those who have received radiotherapy or anti-tumor drug treatment in the past; 5. Suffering from active pulmonary tuberculosis; 6. Esophageal fistula occurred before treatment; 7. Patients with distant metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Adverse reaction rate; | — |
Countries
China
Contacts
Public ContactZhu Linhai
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed